Core Insights - The event held on September 11 focused on the performance explanation of Tianjin-listed companies and highlighted the achievements of Lifesun Pharmaceutical in drug development since 2020 [1] Company Developments - Lifesun Pharmaceutical has made significant progress in new product research and development, with multiple drug approvals achieved [1] - The company has received drug registration certificates for 13 generic products, including Valsartan Amlodipine and Rivaroxaban tablets [1] - A total of 22 product specifications have passed consistency evaluations, and 9 chemical raw material drug applications have been approved [1] Market Strategy - The company aims to enrich its product structure and enhance its marketing system, leading to increased product sales and market share [1] - Lifesun Pharmaceutical is committed to deepening the synergy between research and industrialization to provide accessible quality medications for patients while creating long-term value for investors [1]

Core Viewpoint - The company has approved the use of idle raised funds for cash management, allowing up to RMB 600 million for purchasing short-term financial products with high safety and liquidity, ensuring it does not affect the implementation of investment projects [1] Group 1: Cash Management Details - The company has invested a total of RMB 70 million in structured deposits at Industrial Bank Co., Ltd. Tianjin Branch [1] - There is no related party relationship between the company and Industrial Bank [1] Group 2: Risk Control Measures - The company aims to control risks by purchasing short-term financial products that are safe and liquid, issued by major commercial banks or securities institutions [3] - The finance department is responsible for managing the purchased financial products and will take timely measures if any risk factors affecting fund safety are identified [3] - The audit department will regularly audit the use and custody of the purchased financial products and report to the board and supervisory committee [3] Group 3: Impact on the Company - The company emphasizes compliance and effective control of investment risks while using idle raised funds for cash management, which will not affect daily operations or the normal progress of investment projects [4] - This cash management approach is expected to improve the efficiency of fund usage and generate investment returns for the company and its shareholders [4] Group 4: Previous Cash Management Activities - As of the announcement date, the total amount of idle raised funds used for cash management that are not yet due is RMB 155 million, which is within the approved limits [4]

Core Viewpoint - Tianjin Development (00882.HK) announced a partnership agreement involving its indirect non-wholly owned subsidiary, Lifesun Pharmaceutical, with several investment entities to establish a fund with a total subscription amount of RMB 500 million (approximately HKD 547 million) [1] Group 1 - The fund will primarily invest in equity of unlisted companies and publicly traded stocks issued or traded in a non-public manner, focusing on the health and biotechnology sectors in China [1] - Lifesun Pharmaceutical has committed RMB 174 million (approximately HKD 190 million), representing 34.75% of the total subscription amount for the fund, subject to the terms and conditions of the partnership agreement [1] - The investment areas include innovative drugs, medical devices, in vitro diagnostic devices (IVD), medical services, "CXO" and related pharmaceutical outsourcing services, pharmaceutical-related equipment or consumables, life science instruments and tools, medical technology (including medical big data, AI life sciences, internet healthcare), synthetic biology, bio-agriculture, biomass energy, brain science, medical consumer products, elderly care, traditional Chinese medicine, cell and gene therapy, and other high-quality projects recognized by the investment decision committee [1]

Core Viewpoint - Tianjin Development (00882) announced a partnership agreement involving its indirect non-wholly owned subsidiary, Lifescience Pharmaceutical, to establish a fund with a total subscription amount of RMB 500 million (approximately HKD 547 million) [1] Group 1: Fund Structure and Investment Focus - The fund will primarily invest in equity of unlisted companies and/or stocks issued or traded in a non-public manner by listed companies, focusing on the health and biotechnology sectors in China, including innovative drugs, medical devices, and related services [1] - Lifescience Pharmaceutical has committed RMB 174 million (approximately HKD 190 million), representing 34.75% of the total subscription amount for the fund [1] Group 2: Risk Management and Investment Strategy - By participating in the fund, Lifescience Pharmaceutical's cost risk is limited to its subscribed amount, avoiding additional expenses and debts compared to direct investments [2] - The fund's investment decisions require approval from the investment decision committee, ensuring that decisions are made with the consent of both Jianxin Equity and Teda Private Equity [2] Group 3: Strategic Benefits and Long-term Outlook - Participation in the fund will enhance the group's understanding of the latest developments in the pharmaceutical industry, diversify investment risks, and identify potential strategic partners for future opportunities [3] - The investment is expected to provide opportunities for mergers and acquisitions aligned with the company's strategic goals, improve capital allocation efficiency, and enhance the company's sustainable operational capabilities [3]

Core Viewpoint - Tianjin Development (00882) announced a partnership agreement involving its indirect subsidiary, Lifespring Pharmaceutical (002393), to establish a fund with a total subscription amount of RMB 500 million (approximately HKD 547 million) [1] Group 1: Fund Structure and Investment Focus - The fund will primarily invest in equity of unlisted companies and/or stocks issued or traded in a non-public manner by listed companies, focusing on the health and biotechnology sectors in China, including innovative drugs, medical devices, and related services [1] - Lifespring Pharmaceutical has committed RMB 174 million (approximately HKD 190 million), representing 34.75% of the total subscription amount for the fund [1] Group 2: Risk Management and Investment Strategy - By participating in the fund, Lifespring Pharmaceutical's cost risk is limited to its subscribed amount, avoiding additional expenses and debts compared to direct investments [2] - The fund's investments require approval from the investment decision committee, ensuring that decisions are made with the consent of both Jianxin Equity and Taida Private Equity [2] Group 3: Strategic Benefits and Long-term Outlook - Participation in the fund will enhance the group's understanding of the latest industry developments, diversify investment risks, and identify potential strategic partners for future opportunities [3] - The investment is expected to provide opportunities for industry mergers and acquisitions aligned with the company's strategic development, improving capital allocation efficiency and enhancing sustainable operational capabilities [3]

Group 1 - The company Tianjin Development (00882) announced a financial agreement with Industrial Bank for a structured deposit [1] - The agreement involves an investment of RMB 70 million, equivalent to approximately HKD 76.5864 million [1] - This marks the 10th financial agreement between the company’s indirect non-wholly owned subsidiary, Lifescience Pharmaceutical (002393), and Industrial Bank [1]

格隆汇9月10日丨天津发展(00882.HK)公布，于2025年9月10日，力生制药(公司间接非全资附属公司)与 兴业银行订立第十份兴业银行理财协议，以本金金额人民币7000万元认购另一项结构性存款。 ...

证券代码：002393 证券简称：力生制药 公告编号：2025-061 天津力生制药股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司（以下简称"公司"）于2025年3月19日召开第七届董事会第 五十次会议、2025年4月11日召开2024年度股东大会，审议通过了《关于公司2025年使用 闲置募集资金进行现金管理额度的议案》，同意公司在不影响募集资金投资项目实施的情 况下，使用额度不超过人民币6亿元闲置募集资金购买安全性高、流动性好、由募集户银行 （招商银行、兴业银行或邮储银行）发行的短期理财产品，期限不超过股东大会批准之日 起12个月，在上述额度及期限范围内资金滚动使用。针对上述事项，公司保荐机构发表了 明确的同意意见。具体内容详见公司于2025年3月21日在巨潮资讯网(www.cninfo.com.cn） 披露的《关于公司2025年使用闲置募集资金进行现金管理额度的公告》（公告编号： 2025-025）及《渤海证券关于天津力生制药股份有限公司使用闲置募集资金购买理财产品 的核查 ...

Meeting Overview - The shareholder meeting was held on September 8, 2025, combining on-site and online voting methods [4][5][7] - The total share capital of the company as of the registration date was 257,704,999 shares, with 1,439,980 shares in the repurchase account not entitled to vote, resulting in 256,265,019 shares eligible for voting [5][6] Voting Results - No proposals were rejected during the meeting [1][2] - The controlling shareholder, Tianjin Jinhao Pharmaceutical Co., Ltd., abstained from voting on Proposal 1, with 131,194,851 shares involved [8] - Proposals 2, 5, and 6 were special resolutions that received over two-thirds approval from the voting shareholders and their authorized representatives [8] Legal Compliance - The meeting complied with relevant laws, regulations, and the company's articles of association, as confirmed by the legal opinions provided by Tianjin Sifang Junhui Law Firm [8][9]

渤海证券股份有限公司 关于 天津力生制药股份有限公司 调整 2024 年限制性股票激励计划 证券简称：力生制药 证券代码：002393 回购价格暨回购注销部分激励对象已获授 但尚未解除限售的限制性股票事项 之 独立财务顾问报告 | 第一章 | 释义 | 2 | | --- | --- | --- | | 第二章 | 声明 | 3 | | 第三章 | 基本假设 | 4 | | 第四章 | 激励计划履行的相关审批程序 5 | | | 第五章 | 本次激励股份回购价格调整的具体情况 7 | | | 第六章 | 本次回购注销情况 | 8 | | 第七章 | 独立财务顾问意见 | 9 | | 第八章 | 备查文件 | 9 | 第一章 释义 以下词语如无特殊说明，在本文中具有如下含义： | 力生制药、本公司、 | 指 | 天津力生制药股份有限公司 | | --- | --- | --- | | 公司 | | | | 渤海证券、独立财务 | | | | 顾问、本独立财务顾 | 指 | 渤海证券股份有限公司 | | 问 | | | | | | 《渤海证券股份有限公司关于天津力生制药股份有限公司调整 | | 独立财务顾问报告 ...